CRVS Corvus Pharmaceuticals Inc
5,792
$2.08
$0.05
(2.46%)
| Watchers | 5,792 |
| 52-Wk Low | $1.05 |
| 52-Wk High | $4.19 |
| Market Cap | $130.11M |
| Volume | 307,162.00 |
| 52-Wk High | $4.19 |
| 52-Wk Low | $1.05 |
Corvus Pharmaceuticals, Inc. to Post FY2024 Earnings of ($0.35) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:CRVS)Ticker Report • about 1 month ago
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Research analysts at Cantor Fitzgerald lifted their FY2024 EPS estimates for shares of Corvus Pharmaceuticals in a report issued on Monday...
Share to Feed
Mizuho restated their neutral rating on shares of Corvus Pharmaceuticals (NASDAQ:CRVS - Free Report) in a research note issued to investors on Wednesday morning, Benzinga reports. Mizuho currently...
Mizuho Securities analyst Graig Suvannavejh maintained a Hold rating on Corvus Pharmaceuticals (CRVS Research Report) on March 26 and set a price...
Corvus Pharmaceuticals (NASDAQ:CRVS Get Free Report)s stock had its neutral rating restated by equities research analysts at Mizuho in a research report issued to clients...
Figure 1
Waterfall Plot for Patients in the 200 mg Dose Cohort of the Soquelitinib Phase 1/1b Clinical Trial for Peripheral T Cell Lymphoma. The plot shows the best percent change in...
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PTBURLINGAME, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage...
Anebulo Pharmaceuticals (NASDAQ:ANEB Get Free Report) and Corvus Pharmaceuticals (NASDAQ:CRVS Get Free Report) are both small-cap medical companies, but which is the superior...
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS Get Free Report) was the recipient of a large decrease in short interest during the month of February. As of February 15th, there was short interest...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Poster presentation unveils Corvus' next-generation ITK inhibitor candidates designed to deliver precise T cell modulation for immunology indications
Figure 1
Venn diagram...